127 Startups
  • Sector
  • Participated in
  • Year of participation

Incircular biotechnologies

  • 2019
  • Enabling Technology
  • Venture Challenge
Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Innofluidics

  • 2021
  • Diagnostics
  • Venture Challenge
Liquid biopsy platform for purification and collection of intact CTCs directly from blood

Innofuse

  • 2014
  • Medical Device
  • Venture Challenge
An infusion set that guarantees stability and immediacy of drug administration for preterm babies

inSteps

  • 2022
  • Enabling Technology
  • Venture Challenge
Our in-silico platform can simulate stent-retriever-based thrombectomy in various patient-specific scenarios of varying vascular anatomy and clot characteristics. This allows the medical device industries to evaluate the performance of their novel devices before pre-clinical testing.

Invision-Ex

  • 2023
  • Medical Device
  • Venture Challenge
Invision-ex has developed a bioengineered, lab-grown, human cornea tissue, offering a sustainable, accessible, long-term, and vision corrective solution.

Iprotics

  • 2022
  • Therapeutics
  • Venture Challenge
The Overkleeft group at Leiden University discovered superior proteasome inhibitors, and it is the aim of iProtics to develop these leads to become the first-in-line treatment for Multiple Myeloma patients.

IS-Diagnostics

  • 2010
  • Diagnostics
  • Other
The next generation of clinical diagnostics

JETA molecular

  • 2016
  • Enabling Technology
  • Other
Design, development and commercialization of noninvasive reagent and software solutions for transplant monitoring

Karveel

  • 2015
  • Therapeutics
  • Venture Challenge
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.

Khondrion

  • 2010
  • Other
  • Therapeutics
Khondrion is a clinical stage pharmaceutical company focusing on the development of treatments for mitochondrial (-related) diseases and conditions